Fig. 1A

Mean rFGF Plasma Concentration Versus Time Post IC Administration

Legend:
- 0.33 µg/kg
- 0.65 µg/kg
- 2 µg/kg
- 6 µg/kg
- 12 µg/kg
- 24 µg/kg
- 36 µg/kg
- 48 µg/kg

Y-axis: Mean rFGF-2 Plasma Concentration (pg/mL)

X-axis: Time (hr)

Fig. 1B

Mean rFGF-2 Plasma Concentration-Time Profiles Following IV
Administration. Mean rFGF-2 Plasma Concentration Profile Following
Administration of 36 µg/kg IC Included for Comparison.

Fig. 2

Mean rFGF-2 AUC Vs Dose

Fig. 3

Individual Patient rFGF-2 Plasma Clearance Values

Fig. 4

Individual Patient rFGF-2 Dose-Normalized AUC Versus Dose in Study CS-FG001

FIRST: Analysis Plan

- Primary Efficacy Analysis: change in ETT at 90 days for all evaluable patients by ANOVA
  - Evaluable Patients: subjects with ETT at day 90 who were not revascularized

- Secondary Analyses:
  - ANOVA of Ranks: assigns lowest rank to patients with missing data or revascularized
  - pair-wise comparisons: each dose vs placebo, any FGF vs placebo by ANOVA and ANOVA of Ranks

- Post hoc analyses:
  - by Canadian Cardiovascular Score (CCS)
  - by angina frequency score (AFS)

Figure 5

Figure 6

FIRST: Patient Characteristics

	rFGF-2 (ug/kg)			
	Placebo	0.3	3.0	30
Number of Subjects				
Age (years)	64	63	63	62
Male sex (%)	86	84	80	86
Diabetes (%)	32	35	37	25
Dyslipidemia (%)	93	94	95	91
Hypertension (%)	77	71	68	68
Prior MI (%)	70	65	65	69
Prior CABG (%)	91	89	88	89
Prior PTCA with stent (%)	43	26	42	29
Prior PTCA w/o stent (%)	49	41	32	42
Baseline ETT time (sec)	513	527	525	514
Canadian Cardiovascular Classes II or III (%)	87	87	90	89

FIRST: Patient Disposition

Figure 7

	rFGF-2 (ug/kg)			
	Placebo	0.3	3.0	30
Subjects Enrolled	86	82	84	85
Safety FU: 180 days	82	76	80	83
ETT at 90 / 180 days	82 / 75	75 / 71	79 / 74	77 / 76
Premature Withdrawal	4	6	4	2
– Death	1	1	3	1
– Adverse Event	1	2	1	0
– Withdrew Consent	1	1	0	1
– Lost to Follow-up	0	1	0	0
– Protocol Deviation /Violation	0	1	0	0
– Nonclassified	1	0	0	0
Revascularized Subjects Excluded from Analysis	5	5	3	6

Figure 8

FIRST: Safety

|	Placebo	rFGF-2 (ug/kg)		
		0.3	3.0	30
Number of Subjects	86	82	84	85
All Serious Events	29 (34%)	29 (35%)	22 (26%)	35 (41%)
Deaths	1	1	3	1
Carcinoma	1	0	1	1
Cardiac Events				
Admissions for Angina/Chest Pain	18	12	8	21
Cardiac Arrest	0	1	2	1
Myocardial Infarct	5	2	5	5
Revascularizations	5	5	3	6
Laboratory Findings				
Clearance: < 60 mL/min	4	0	1	3
Creatinine > 2.5 mg/dL	4	5	None	4
Proteinuria > 300 mg/24 h	4	5	4	5

Figure 9

Change in Exercise Time

Primary Efficacy Analysis at Day 90: overall p = .64

Revascularized subjects and subjects with missing ETT excluded

Day 180: overall p = 0.44

Change in Angina Frequency Score

Day 90: overall p = 0.035*   *Revascularized subjects and*

Day 180: overall p = 0.38   *subjects with no data excluded*

Figure 10

Seattle Angina Questionnaire
Change in Other Domains

Figure 11

All P values > .05

Change in Short Form-36

Change in Physical Component Summary Score

Day 90 overall p = .21

Day 90

Day 180

Revascularized subjects and
subjects with no data excluded

p = .033 for All FGF

Legend:
- Placebo
- 0.3 μg/kg
- 3.0 μg/kg
- 30 μg/kg

Figure 12

Figure 13

Stratified by Baseline CCS Class 3 or 4

Angina Frequency Score

Day 90 overall p = 0.04*

Day 180 overall p = 0.21

ETT

Day 90 overall p = 0.78

Day 180 overall p = 0.23

Day 90
Day 180

Figure 14

Stratified by Baseline AFS ≤ 40

Day 90

Day 180

Angina Frequency Score

Change in AFS

30   3   0.3   **Placebo**

Day 90 overall p = 0.021*

Day 180 overall p = 0.12

ETT

Change in Exercise Time (sec)

30   3   0.3   **Placebo**

Day 90 overall p = 0.37

Day 180 overall p = 0.43